

#AHA23

SUSTAINED BLOOD PRESSURE REDUCTION WITH THE RNA INTERFERENCE THERAPEUTIC, ZILEBESIRAN: PRIMARY RESULTS FROM KARDIA 1, A PHASE 2 STUDY IN PATIENTS WITH HYPERTENSION

George Bakris¹, Manish Saxena^{2,3}, Anil Gupta⁴, Fadi Chalhoub⁵, Maxwell Lasko⁶, Nune Makarova⁶, Nitender Goyal⁶, Weinong Guo⁶, Dion Zappe⁶, Akshay S Desai⁷

¹University of Chicago Medicine, Chicago, IL, USA; ²Barts Health NHS Trust, London, UK; ³Queen Mary University of London, UK; ⁴Albion Finch Medical Centre, Toronto, ON, Canada; ⁵Clinical Neuroscience Solutions, Jacksonville, FL, USA; ⁶Alnylam Pharmaceuticals, Cambridge, MA, USA; ⁷Cardiovascular Division, Brigham & Women's Hospital, Boston, MA, USA

Presented at the American Heart Association Scientific Sessions,
November 11–13, 2023, Philadelphia, PA, USA



PRESENTER DISCLOSURES

George Bakris, MD

FINANCIAL DISCLOSURE:

George Bakris has received consulting fees from Alnylam Pharmaceuticals, AstraZeneca, Bayer, GlaxoSmithKline, InREGEN, Ionis, Janssen, KBP Biosciences, and Novo Nordisk.

UNLABELED/UNAPPROVED USES DISCLOSURE:

Zilebesiran is an investigational product in development for treatment of patients with hypertension.

An Unmet Need for Novel Antihypertensive Therapeutics

Hypertension

- Uncontrolled hypertension is a leading cause of morbidity and mortality^{1,2}
- Despite availability of effective antihypertensives, many adults with hypertension are untreated and up to 80% have uncontrolled disease, both globally and in the USA^{3,4}


Zilebesiran

- Zilebesiran is an investigational subcutaneous RNA interference therapeutic that targets hepatic AGT synthesis
- Phase 1 study data have demonstrated sustained, dose-dependent reductions in serum AGT levels and blood pressure through 24 weeks after a single dose of zilebesiran in patients with mild-to-moderate hypertension⁵

Objective

- To evaluate the efficacy and safety of different dosing regimens of zilebesiran monotherapy in patients with mild-to-moderate hypertension from the Phase 2 KARDIA-1 study


Zilebesiran Mediates Hepatic AGT Reduction



AGT, angiotensinogen; des(Ang1)AGT, des(Ang1)angiotensinogen; GalNAc, *N*-acetylgalactosamine; RNA, ribonucleic acid; siRNA, small interfering ribonucleic acid.

1. Zhou B *et al. Nat Rev Cardiol* 2021;18:785–802; 2. Danaei G *et al. PLoS Med* 2009;6:e1000058; 3. World Health Organization. Hypertension. 2021. Available from: www.who.int/news-room/fact-sheets/detail/hypertension (Accessed September 14, 2023); 4. Centers for Disease Control and Prevention. Estimated hypertension prevalence, treatment, and control among U.S. adults. 2022. Available from: <https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html> (Accessed September 14, 2023); 5. Desai AS *et al. N Engl J Med* 2023;389:228–38.

KARDIA₁: A Randomized, Double-Blind, Dose-Ranging Study of Zilebesiran in Patients with Mild-to-Moderate Hypertension




- Rescue antihypertensive medication was permitted after Month 3 assessments and was discontinued by Month 5 for Month 6 assessments
- Assessments of patients receiving or within 2 weeks of stopping rescue antihypertensive medication were excluded from analysis to investigate effects of zilebesiran monotherapy

Baseline Demographics Were Balanced Across Groups

		Placebo	Zilebesiran				Zilebesiran total
			150 mg Q6M	300 mg Q6M	300 mg Q3M	600 mg Q6M	
Disposition	Randomized, n ^a	79	79	78	79	79	315
	Included in analysis set, n ^a	75	78	73	75	76	302
	Completed 6-month DB period, n (%)	70 (92)	70 (90)	70 (96)	68 (91)	69 (91)	277 (92)
	Discontinued study during 6-month DB period, n (%)	5 (7)	8 (10)	3 (4)	5 (7) ^b	5 (7) ^b	21 (7) ^b
	Discontinued study owing to AE, n	0	1	0	0	0	1
Demographics and clinical characteristics	Analysis set, n ^a	75	78	73	75	76	302
	Mean age, years (SD)	57 (11)	56 (11)	56 (10)	58 (11)	57 (10)	57 (10)
	Male sex, n (%)	37 (49)	39 (50)	44 (60)	45 (60)	45 (59)	173 (57)
	BMI, ≥30 kg/m ² , n (%)	37 (49)	46 (59)	46 (63)	40 (53)	45 (59)	177 (59)
	Race, n (%) ^c						
	Asian	5 (7)	4 (5)	2 (3)	7 (9)	5 (7)	18 (6)
	Black or African American	18 (24)	20 (26)	17 (23)	19 (25)	19 (25)	75 (25)
	White	52 (69)	53 (68)	54 (74)	48 (64)	52 (68)	207 (69)
	24-hour mean ambulatory SBP/DBP, mmHg (SD)	141 (8)/ 82 (8)	141 (9)/ 82 (8)	143 (9)/ 82 (9)	142 (8)/ 82 (9)	143 (9)/ 81 (8)	142 (9)/ 82 (8)
	Office SBP/DBP, mmHg (SD)	143 (13)/ 88 (11)	142 (11)/ 87 (10)	143 (11)/ 89 (9)	140 (11)/ 85 (9)	141 (11)/ 86 (9)	141 (11)/ 87 (9)
eGFR ≥60 mL/min/1.73 m ² , n (%)	64 (85)	68 (87)	70 (96)	69 (92)	68 (90)	275 (91)	

^aDuring the study, 16 patients were randomized from Ukraine in January–February 2022 before geographic conflict started. Owing to the challenge of data collection and cleaning, these patients were excluded from the analyses. One patient in the placebo group was not dosed and was also excluded from analysis. ^bTwo patients in the 300 mg Q3M group and two patients in the 600 mg Q6M group who discontinued from study treatment during the 6-month DB period are in the safety follow-up period at the time of data cut. These four patients do not have a Month 6 visit and are not considered to have completed the 6-month DB period. ^cOne patient in the 150 mg Q6M group was American Indian or Alaska Native; one patient in the 300 mg Q3M group was Native Hawaiian or Other Pacific Islander.


Dose-Dependent Reductions in AGT Observed Through 6 Months



■ Placebo	n=	74	71	70	71	71	69	68	69
● 150 mg Q6M	n=	78	78	77	74	74	71	70	70
● 300 mg Q6M	n=	73	72	73	72	72	71	70	70
▲ 300 mg Q3M	n=	75	73	72	72	72	70	70	68
◆ 600 mg Q6M	n=	76	71	73	73	71	69	69	69

- Mean reductions in serum AGT were sustained, with reductions of 88% for 150 mg Q6M, 93% for 300 mg Q6M, 98% for 300 mg Q3M, and 96% for 600 mg doses of zilebesiran at Month 6
- Through Month 6, AGT reduction was correlated with SBP change (r [95% CI]: 0.354 [0.298, 0.408]); data on file

Dose-Dependent Reductions in AGT Observed Through 6 Months




● 150 mg Q6M	n=	78	78	77	74	74	71	70	70
◆ 300 mg Q6M	n=	73	72	73	72	72	71	70	70
▲ 300 mg Q3M	n=	75	73	72	72	72	70	70	68
◆ 600 mg Q6M	n=	76	71	73	73	71	69	69	69

- Mean reductions in serum AGT were sustained, with reductions of 88% for 150 mg Q6M, 93% for 300 mg Q6M, 98% for 300 mg Q3M, and 96% for 600 mg doses of zilebesiran at Month 6
- Through Month 6, AGT reduction was correlated with SBP change (r [95% CI]: 0.354 [0.298, 0.408]); data on file

Significant Decreases in ABPM SBP with All Zilebesiran Regimens

Change from Baseline to Month 3 in 24-Hour Mean Ambulatory SBP




Month 3 (Primary Endpoint)	150 mg Q6M	300 mg Q3M and Q6M	600 mg Q6M
LSMD vs placebo, mmHg (95% CI) ^a	-14.1 (-19.2, -9.0), p=4.2E-10	-16.7 (-21.2, -12.3), p=1.0E-12	-15.7 (-20.8, -10.6), p=1.0E-12

Blood pressure assessments were censored if taken while patients were receiving or within 2 weeks after stopping any rescue medication. Data points are staggered for visualization. ^aAdjusted 95% CIs and p values for the Month 3 primary analysis are based on Dunnett's test. ABPM, ambulatory blood pressure monitoring; BL, baseline; CI, confidence interval; LSM, least-squares mean; LSMD, LSM difference; Q3M, every 3 months; Q6M, every 6 months; SBP, systolic blood pressure.

Significant Decreases in ABPM SBP with All Zilebesiran Regimens

Change from Baseline to Month 6 in 24-Hour Mean Ambulatory SBP




Month 6 (Key Secondary Endpoint)	150 mg Q6M	300 mg Q6M	300 mg Q3M	600 mg Q6M
LSMD vs placebo, mmHg (95% CI)	-11.1 (-15.8, -6.4), p=4.5E-06	-14.5 (-19.1, -9.9), p=1.8E-09	-14.1 (-18.9, -9.4), p=9.1E-09	-14.2 (-18.9, -9.5), p=5.8E-09

Blood pressure assessments were censored if taken while patients were receiving or within 2 weeks after stopping any rescue medication. Data points are staggered for visualization. ^aAdjusted 95% CIs and *p* values for the Month 3 primary analysis are based on Dunnett's test. ABPM, ambulatory blood pressure monitoring; BL, baseline; CI, confidence interval; LSM, least-squares mean; LSMD, LSM difference; Q3M, every 3 months; Q6M, every 6 months; SBP, systolic blood pressure.

Significant Decreases in Office SBP with All Zilebesiran Regimens

Change from Baseline to Month 3 in Office SBP




Month 3 (Key Secondary Endpoint)	150 mg Q6M	300 mg Q3M and Q6M	600 mg Q6M
LSMD vs placebo, mmHg (95% CI)	-9.6 (-13.8, -5.3), p=1.3E-05	-12.0 (-15.7, -8.3), p=8.0E-10	-9.1 (-13.4, -4.8), p=3.8E-05

Blood pressure assessments were censored if taken while patients were receiving or within 2 weeks after stopping any rescue medication.
 CI, confidence interval; LSM, least-squares mean; LSMD, LSM difference; Q3M, every 3 months; Q6M, every 6 months; SBP, systolic blood pressure.

Significant Decreases in Office SBP with All Zilebesiran Regimens

Change from Baseline to Month 6 in Office SBP



Month 6 (Key Secondary Endpoint)	150 mg Q6M	300 mg Q6M	300 mg Q3M	600 mg Q6M
LSMD vs placebo, mmHg (95% CI)	-7.5 (-12.4, -2.7), p=0.0025	-10.5 (-15.3, -5.7), p=2.5E-05	-12.1 (-17.2, -7.1), p=2.8E-06	-10.2 (-15.1, -5.3), p=5.9E-05

Blood pressure assessments were censored if taken while patients were receiving or within 2 weeks after stopping any rescue medication.
 CI, confidence interval; LSM, least-squares mean; LSMD, LSM difference; Q3M, every 3 months; Q6M, every 6 months; SBP, systolic blood pressure.

Consistent Treatment Response Observed with Zilebesiran


- The proportion of patients and odds of achieving 24-hour mean ambulatory SBP of <130 mmHg and/or reduction of ≥ 20 mmHg without additional antihypertensives at Month 6 were significantly higher with all zilebesiran regimens versus placebo

	Placebo (N=75)	Zilebesiran			
		150 mg Q6M (N=78)	300 mg Q6M (N=73)	300 mg Q3M (N=75)	600 mg Q6M (N=76)
Response criteria met, n (%) ^a	5 (7)	24 (31)	37 (51)	29 (39)	36 (47)
Zilebesiran vs placebo					
Odds ratio	–	6.75	19.73	10.73	17.93
95% CI	–	2.35, 19.37	6.84, 56.89	3.76, 30.64	6.24, 51.52
<i>p</i> value	–	0.0004	3.4E–08	9.3E–06	8.4E–08

Treatment response rate defined as proportion of patients with 24-hour mean SBP assessed by ambulatory <130 mmHg and/or reduction ≥ 20 mmHg without additional antihypertensive medications at Month 6. ^aAssessments are missing for 43 patients. CI, confidence interval; Q3M, every 3 months; Q6M, every 6 months; SBP, systolic blood pressure.

Consistent 24-Hour SBP Control Observed Through Month 3

Hourly Mean SBP and Change from Baseline in Hourly Mean SBP Assessed by Ambulatory BPM over 24 Hours



- SBP data to Month 6 were consistent with SBP data to Month 3
- DBP data to Month 3 and Month 6 were consistent with SBP data

Zilebesiran Had a Favorable Safety Profile Over 6 Months

AE, n (%)	Placebo (N=75)	Zilebesiran				Zilebesiran total (N=302)
		150 mg Q6M (N=78)	300 mg Q6M (N=73)	300 mg Q3M (N=75)	600 mg Q6M (N=76)	
At least 1 serious AE	5 (7)	0	1 (1)	4 (5)	6 (8)	11 (4)
At least 1 severe AE	3 (4)	0	1 (1)	5 (7)	4 (5)	10 (3)
At least 1 study drug-related AE	6 (8)	12 (15)	12 (16)	14 (19)	13 (17)	51 (17)
Study drug-related AEs occurring in >5% of patients						
Injection site reaction	0	3 (4)	4 (6)	8 (11)	4 (5)	19 (6)
Hyperkalemia	1 (1)	4 (5)	3 (4)	4 (5)	5 (7)	16 (5)
Additional AEs of clinical interest (any relatedness)						
Hyperkalemia ^a	2 (3)	5 (6)	4 (6)	5 (7)	5 (7)	19 (6)
Hypotension	1 (1)	3 (4)	3 (4)	3 (4)	4 (5)	13 (4)
Hepatic AE ^b	1 (1)	2 (3)	2 (3)	4 (5)	1 (1)	9 (3)
Acute renal failure ^c	0	1 (1)	1 (1)	1 (1)	1 (1)	4 (1)

- No drug-related AEs were classified as serious or severe
- Drug-related AEs leading to discontinuation of zilebesiran were orthostatic hypotension (n=2), BP elevation (n=1), and ISR (n=1)
- Most hyperkalemia AEs were mild and did not require intervention; none were associated with AKI or led to study drug discontinuation
 - Analysis of serial laboratory testing suggested that most instances of hyperkalemia resolved upon repeat measurement
- Hypotension AEs were mild or moderate, non-serious, and transient; a single event with zilebesiran 300 mg Q3M was treated with normal saline
- One death due to cardiopulmonary arrest occurred in a patient receiving zilebesiran 300 mg Q3M; it was not classified as drug-related

Definitions based on MedDRA terminology. Potential hypotension AEs (including AEs of hypotension plus additional potentially related terms) were observed in 5 patients (7%) in the placebo group, 6 patients (8%) each in the 150 mg and 300 mg Q6M groups, 5 patients (7%) in the 300 mg Q3M group, and 7 patients (9%) in the 600 mg Q6M group (zilebesiran total, 24 patients [8%]). ^aHyperkalemia AEs include AEs mapped to the customized query of hyperkalemia, blood potassium increased, and blood potassium abnormal. ^bHepatic AEs include AEs mapped to the SMQ drug-related hepatic disorders, both narrow and broad terms. ^cAcute renal failure AEs include AEs mapped to the SMQ acute renal failure, both narrow and broad terms. AE, adverse event; AKI, acute kidney injury; BP, blood pressure; ISR, injection site reaction; MedDRA, Medical Dictionary for Regulatory Activities; Q3M, every 3 months; Q6M, every 6 months; SMQ, Standardised MedDRA Query.

Conclusions

- In KARDIA-1, single subcutaneous doses of zilebesiran resulted in clinically meaningful and significant reductions in SBP compared with placebo at Month 3, that were sustained through Month 6
 - Tonic blood pressure control was demonstrated by consistent 24-hour mean SBP reductions throughout the dosing period across all zilebesiran regimens
- Zilebesiran demonstrated an encouraging safety profile over 6 months; rates of serious or severe AEs were low, and only mild or moderate non-serious drug-related AEs were observed across all zilebesiran regimens
 - Most hyperkalemia AEs were mild, transient, and resolved without intervention, incidence of hypotension events was low, and no clinically relevant changes in renal or hepatic function were observed
- These data further support the potential for quarterly or biannual dosing of subcutaneous zilebesiran in achieving a consistent pharmacodynamic effect and effective blood pressure reduction through 6 months
- Zilebesiran is being further evaluated as an add-on therapy for treatment of hypertension in the ongoing KARDIA-2 (NCT05103332) Phase 2 study

**Thank you to the patients, their families, investigators, study staff, and collaborators
for their participation in the zilebesiran KARDIA-1 study**